Tag: People
Breaking News
iLearn Announces the Release of EggHeads: An Edutainment Platform for Web3 or Web2 Companies Where Virtually Any Prize Is Possible
Founded by Edozie Izegbu, a software engineer who attended Oxford University with a focus on building socially impactful software from the get go. He worked at Blockchain.com and Carbon (Challenger bank in Nigeria).
iLearn has a distributed team hailing from PWC, McKinsey, Blockchain.com, Carbon and others, where they are committed to building decentralized ownership and reward architecture into the educational model.
The iLearn platform priorities incentivised learning, promoting engagement and motivation within a variety of subjects. The first of many applications to be released on the iLearn platform is Eggheads, a live puzzle quiz platform where players can win real prizes from crypto to NFTs to your favorite sports game tickets. Creating a new kind of "Edutainment" system for any web3 company to build on top of.
Platforms and release date
The Eggheads platform is coming to Desktop Web and Mobile Web in March and in Q2 for iOS/Android and allows players to keep all their crypto in the app with no knowledge of decentralized wallets or the wider crypto ecosystem necessary. If you know how to answer questions you can win real prizes.
How Does Eggheads Work
The Eggheads brain game trains the mind while also feeding the wallets with real cash, crypto, and NFT prizes. The application functions as an RPG puzzle platform that allows players to fight in Battle Royale (player vs. all) or PvP (player vs. player) trivia games. The goal of Eggheads is to provide a seamless live game show experience with everyone in mind. Crypto experts and novices alike will be able to compete. Play against your friends or top contenders in front of an audience.
Why Eggheads vs. standard play to earn course-based learning?
Eggheads won't replace standard course-based learning. Deep end-to-end education requires structure and guidance. However, Eggheads does fill the niche of incentivizing deeper and more targeted learning for individuals already interested in specific subjects.
Why doesn't course-based learning work for this use case?
The biggest issue is engagement. An engaging and fun mechanism is crucial for the continued learning of targeted subjects. In this sense, Eggheads will provide both a monetary and social incentive to participate in the ecosystem. Users will be enticed by the rewards but will ultimately remain engaged due to social interaction and competition with other people interested in the same educational topics.
Exciting Partnerships & What to Expect
The initial launch of Eggheads will kick off with Battle Royale style category-based trivia games. Users will compete against each other in a survivor-style game. Correct answers are rewarded, and the wrong answers could knock you out of the competition!
We mentioned exciting partnerships in the title and we meant it! The Eggheads pilot will be launched with revolutionary companies in the blockchain ecosystem. These first Battle Royale trivia games will be hosted by:
- Polygon
- Neon Labs
- Velas
We're looking forward to partnering with enterprises to power their learning incentivisation platforms with quiz games and courses.
Keep Up with iLearn
Stay in the loop with Eggheads development through our Discord, Twitter, and Medium. We have a couple more exciting partnerships to announce in the coming month and can't wait to share. Additionally, they will be releasing details and content related to our partner-hosted Eggheads tournaments.
To sign up to Eggheads as a Polygon/Velas/Neon(Solana) project click here ( https://forms.gle/fScqZSD1uxi7ztmi9 ) and engage your community with Tokens and NFTs with fun quizzes.
To pre-register for the Egghead Alpha with upcoming quiz games as a contestant here ( https://forms.gle/BmFqEtUMHFQ54keh7 ) to win big.
Find out more about iLearn
Twitter: https://twitter.com/EggheadsGame
Discord: https://discord.com/invite/UpqZpT5vej
Medium: https://medium.com/@iLearn
Alpha Whitelist Registration: https://forms.gle/BmFqEtUMHFQ54keh7
Build on iLearn: https://forms.gle/fScqZSD1uxi7ztmi9
LinkedIn: https://www.linkedin.com/in/edozie/
Media Contact
Brand: iLearn
Contact: Edozie Izegbu
Email: edozie@ilearn.games
Website: https://ilearn.games/
SOURCE: iLearn
Copyright 2022 ACN Newswire. All rights reserved. www.acnnewswire.comiLearn launches a new mobile NFT game app disrupting the education industry, gaming industry and pioneering Learn to Earn. iLearn, a learning incentivization platform, aims to use blockchain technology to create a rewarding, engaging, and fun way to learn. Eggheads will be the first program (game) launched on iLearn.
Honda to Issue U.S. Dollar-Denominated Green Bonds (Unsecured Straight Bonds) to Accelerate its Environmental Initiatives
 |
Since its founding in 1948, Honda has been conducting its corporate activities based on its original desire to "help people and society" and "expand people's life's potential." In light of changes happening to our society, Honda believes that working in pursuit of the "elimination of its environmental impact" and "realization of safety protecting precious human lives" are values Honda should provide in the future. Based on this belief, Honda has been working comprehensively to address challenges in the areas of the environment and safety. In the area of the environment, Honda is striving to realize carbon neutrality (net-zero CO2 emissions) for all products and corporate activities Honda is involved in by 2050.
By allocating the proceeds from the issuance of the Green Bonds to eligible green projects including the development of zero-emission vehicles such as EVs and FCVs, Honda will further accelerate its initiatives toward the realization of a society that aims for zero environmental impact.
(1) Projects that fit within the eligible Green Projects categories specified in the Honda Sustainable Finance Framework.
(2) For the issuance of these Green Bonds, Honda has developed a Sustainable Finance Framework (the "Framework") and obtained a Second Party Opinion from Vigeo Eiris, an independent entity, that the Framework is aligned with the Green Bond Principles 2021 (the "GBP"), the Social Bond Principles 2021 (the "SBP"), and the Sustainability Bond Guidelines 2021 (the "SBG") as administered by the International Capital Market Association ("ICMA").
- Honda Sustainable Finance Framework: URL:
https://global.honda/investors/stock_bond/rating_bond.html
- Second Party Opinion provided by Vigeo Eiris: URL:
https://vigeo-eiris.com/spo_honda_sustainable_framework
This document does not constitute an offer to sell or a solicitation of an offer to buy any securities. The securities described herein have not been approved or disapproved by any regulatory authority, nor has any such authority passed upon the accuracy or adequacy of the shelf registration statement, the base prospectus contained therein or the supplements to the base prospectus.
Copyright 2022 JCN Newswire. All rights reserved. www.jcnnewswire.comHonda Motor Co., Ltd. today announced that the company will issue U.S. dollar-denominated Green Bonds totaling US$2.75 billion for its initiatives toward the realization of a society that aims for zero environmental impact.
Flooding moves RAAF aircraft at Base Amberley
The south-west Brisbane base is home to F/A-18F Super Hornet multi-role fighters, KC-30A Multi-Role Tanker Transport aircraft, and C-17A Globemaster III heavy transport aircraft. 
Eisai Initiates Submission of Application Data Under the Prior Assessment Consultation System in Japan with the Aim of Obtaining Early Approval for Investigational Anti-Amyloid...
The PMDA's process, known as "prior assessment consultation", is conducted at the development stage before the new drug application submission, which is based on available quality, non-clinical and clinical data. By identifying and resolving any potential issues prior to submission, the aim is to shorten application review time.
Based on discussions with the Ministry of Health, Labour and Welfare (MHLW) and PMDA, Eisai applied to PMDA for permission to utilize the "prior assessment consultation" process for lecanemab with the aim of shortening the review period. The agency approved Eisai's request and Eisai has submitted the non-clinical lecanemab data to PMDA. The additional data of the application package will be submitted hereafter. Eisai plans to obtain the primary endpoint data from Clarity AD study in the fall of 2022, and based on the results of the study, aims to file for the manufacturing and marketing approval in Japan during Eisai's fiscal year 2022.
In September 2021, Eisai initiated a rolling submission to the U.S. Food and Drug Administration (FDA) of a Biologics License Application (BLA) for lecanemab, an investigational agent under the Accelerated Approval pathway for the treatment of early AD with confirmed amyloid pathology, and expects to complete this rolling submission in the beginning of Eisai's fiscal year 2022. Based on the results of Clarity AD study as the confirmatory study, Eisai plans to submit for full approval of lecanemab to the U.S. FDA during fiscal year 2022. Eisai and Biogen are committed to providing innovative treatments to persons living with early AD, their families and healthcare professionals who are waiting for new treatment options, as early as possible.
About the Prior Assessment Consultation System
The prior assessment consultation is conducted at the development stage before new drug application submission based on available quality, non-clinical and clinical data. By identifying and resolving any potential issues prior to submission, the aim is to shorten application review time.
About Lecanemab (BAN2401)
Lecanemab is an investigational humanized monoclonal antibody for Alzheimer's disease (AD) that is the result of a strategic research alliance between Eisai and BioArctic. Lecanemab selectively binds to neutralize and eliminate soluble, toxic amyloid-beta (Aβ) aggregates (protofibrils) that are thought to contribute to the neurodegenerative process in AD. As such, lecanemab may have the potential to have an effect on disease pathology and to slow down the progression of the disease. Currently, lecanemab is being developed as the only anti- Aβ antibody that can be used for the treatment of early AD without the need for titration. With regard to the results from pre-specified analysis at 18 months of treatment, Study 201 demonstrated reduction of brain Abeta accumulation (P<0.0001) and slowing of disease progression measured by ADCOMS* (P<0.05) in early AD subjects. The study did not achieve its primary outcome measure** at 12 months of treatment. The Study 201 open-label extension was initiated after completion of the Core period and a Gap period off treatment of 9-59 months (average of 24 months, n=180 from core study enrolled) to evaluate safety and efficacy, and is underway.
Currently, lecanemab is being studied in a confirmatory Phase 3 clinical study in symptomatic early AD (Clarity-AD), following the outcome of the Phase 2 clinical study (Study 201). Since July 2020 the Phase 3 clinical study (AHEAD 3-45) for individuals with preclinical AD, meaning they are clinically normal and have intermediate or elevated levels of amyloid in their brains, is ongoing. AHEAD 3-45 is conducted as a public-private partnership between the Alzheimer's Clinical Trial Consortium that provides the infrastructure for academic clinical trials in Alzheimer's Disease and related dementias in the U.S, funded by the National Institute on Aging, part of the National Institutes of Health, Eisai and Biogen. Furthermore, Eisai has initiated a lecanemab subcutaneous dosing Phase 1 study. Eisai obtained the global rights to study, develop, manufacture and market lecanemab for the treatment of AD pursuant to an agreement concluded with BioArctic in December 2007. In March 2014 Eisai and Biogen entered into a joint development and commercialization agreement for lecanemab and the parties amended that agreement in October 2017.
* Developed by Eisai, ADCOMS (AD Composite Score) combines items from the ADAS-Cog (Alzheimer's Disease Assessment Scale-cognitive subscale), CDR (Clinical Dementia Rating) and the MMSE (Mini-Mental State Examination) scales to enable a sensitive detection of changes in clinical functions of early AD symptoms and changes in memory. The ADCOMS scale ranges from a score of 0.00 to 1.97, with higher score indicating greater impairment.
** An 80% or higher estimated probability of demonstrating 25% or greater slowing in clinical decline at 12 months treatment measured by ADCOMS from baseline compared to placebo.
About the Collaboration between Eisai and Biogen for Alzheimer's Disease
Eisai and Biogen are collaborating on the joint development and commercialization of AD treatments. Eisai serves as the lead in the co-development of lecanemab.
About the Collaboration between Eisai and BioArctic for Alzheimer's Disease
Since 2005, BioArctic has had a long-term collaboration with Eisai regarding the development and commercialization of drugs for the treatment of AD. The commercialization agreement on the lecanemab antibody was signed in December 2007, and the development and commercialization agreement on the antibody lecanemab back-up for AD, which was signed in May 2015. Eisai is responsible for the clinical development, application for market approval and commercialization of the products for AD. BioArctic has no development costs for lecanemab in AD.
About Eisai Co., Ltd.
Eisai Co., Ltd. is a leading global pharmaceutical company headquartered in Japan. Eisai's corporate philosophy is based on the human health care (hhc) concept, which is to give first thought to patients and their families, and to increase the benefits that health care provides to them. With a global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology.
Leveraging the experience gained from the development and marketing of a treatment for Alzheimer's disease, Eisai aims to establish the "Eisai Dementia Platform." Through this platform, Eisai plans to deliver novel benefits to those living with dementia and their families through constructing a "Dementia Ecosystem," by collaborating with partners such as medical organizations, diagnostic development companies, research organizations, and bio-ventures in addition to private insurance agencies, finance industries, fitness clubs, automobile ma kers, retailers, and care facilities. For more information about Eisai Co., Ltd., please visit https://www.eisai.com.
About Biogen
As pioneers in neuroscience, Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological diseases as well as related therapeutic adjacencies. One of the world's first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Sir Kenneth Murray, and Nobel Prize winners Walter Gilbert and Phillip Sharp. Today, Biogen has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, and is providing the first and only approved treatment to address a defining pathology of Alzheimer's disease. Biogen is also commercializing biosimilars and focusing on advancing the industry's most diversified pipeline in neuroscience that will transform the standard of care for patients in several areas of high unmet need.
In 2020, Biogen launched a bold 20-year, $250 million initiative to address the deeply interrelated issues of climate, health, and equity. Healthy Climate, Healthy Lives aims to eliminate fossil fuels across the company's operations, build collaborations with renowned institutions to advance the science to improve human health outcomes, and support underserved communities.
Biogen Safe Harbor
This news release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, about the potential clinical effects of lecanemab; the potential benefits, safety and efficacy of lecanemab; potential regulatory discussions, submissions and approvals and the timing thereof; the expected data readout for the Clarity AD study; the treatment of Alzheimer's disease; the anticipated benefits and potential of Biogen's collaboration arrangements with Eisai; the potential of Biogen's commercial business and pipeline programs, including lecanemab; and risks and uncertainties associated with drug development and commercialization. These statements may be identified by words such as "aim," "anticipate," "believe," "could," "estimate," "expect," "forecast," "intend," "may," "plan," "possible," "potential," "will," "would" and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical studies may not be indicative of full results or results from later stage or larger scale clinical studies and do not ensure regulatory approval. You should not place undue reliance on these statements or the scientific data presented.
These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including without limitation unexpected concerns that may arise from additional data, analysis or results obtained during clinical studies, including the Clarity AD clinical trial and AHEAD 3-45 study; the occurrence of adverse safety events; risks of unexpected costs or delays; the risk of other unexpected hurdles; regulatory submissions may take longer or be more difficult to complete than expected; regulatory authorities may require additional information or further studies, or may fail or refuse to approve or may delay approval of Biogen's drug candidates, including lecanemab; actual timing and content of submissions to and decisions made by the regulatory authorities regarding lecanemab; uncertainty of success in the development and potential commercialization of lecanemab; failure to protect and enforce Biogen's data, intellectual property and other proprietary rights and uncertainties relating to intellectual property claims and challenges; product liability claims; third party collaboration risks; and the direct and indirect impacts of the ongoing COVID-19 pandemic on Biogen's business, results of operations and financial condition. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from Biogen's expectations in any forward-looking statement. Investors should consider this cautionary statement as well as the risk factors identified in Biogen's most recent annual or quarterly report and in other reports Biogen has filed with the U.S. Securities and Exchange Commission. These statements are based on Biogen's current beliefs and expectations and speak only as of the date of this news release. Biogen does not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.
Copyright 2022 JCN Newswire. All rights reserved. www.jcnnewswire.comEisai Co., Ltd. and Biogen Inc. announced today that Eisai has initiated a submission to the Pharmaceuticals and Medical Devices Agency (PMDA) of application data under the prior assessment consultation system in Japan for the investigational anti-amyloid beta (Abeta) protofibril antibody lecanemab (BAN2401).
Latest Intelligence
